The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Labatec’s extensive portfolio includes more than 70 high-quality products, manufactured in Europe and Canada, and supplied to 14 countries comprising Switzerland, Austria, the Middle East, and North Africa.
Labatec is recognized as partner of choice for Swiss hospitals with an extensive portfolio of injectables covering essential therapeutical areas (anti-infectives, anesthetics, antiemetics, and oncology).
Labatec develops and markets medicines that contribute to improving patients’ quality of life.
For more information, please visit www.labatecpharma.com